This study supports the integration of genetic testing for FGF14 expansions in the diagnostic work-up of MSA, particularly for patients with early-onset cerebellar ataxia, parkinsonism and autonomic dysfunction. This evidence concerns the gene FGF14 and aceruloplasminemia.